Aurinia Pharmaceuticals Stock Tanks 30% After Reporting Q4 Results

Shares of Aurinia Pharmaceuticals Inc. (AUPH) tanked nearly 30% on Monday morning after the company reported its fourth-quarter results, with net loss widening from last year.

AUPH is currently trading at $11.52, down $4.72 or 29.03%, on the Nasdaq.

Net loss for the quarter widened to $33.3 million or $0.25 per share from $8.1 million or $0.06 per share last year. Revenues for the quarter more-than-halved to $23.4 million from $50.0 million last year.

For fiscal year 2022, the company is providing net revenue guidance of $115 to $135 million from sales of Lupkynis.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Follow RTT